FGF2 and neoplasm: Here, we demonstrated that bevacizumab treatment induced tumor hypoxia to upregulate the expression of FGFBP1 in tumor cells (Supplemental Figure 15), which activated the FGF2/FGFR1 signaling pathway to promote HSCs’ transformation into multiple phenotypes, including an “immunogenic” phenotype (Supplemental Figure 16) as reported previously (59).